PharmaTher Holdings Launches Personaliz3D Peptides™ Division After Favorable FDA Advisory Committee Recommendations

FDA Advisory Committee Recommendations Pave Regulatory Pathway

Personaliz3D Peptides™ was launched following pivotal regulatory progress in the U.S. The FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptide compounds—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—for inclusion on the Section 503A Bulks List. This designation pertains to compounded drug products prepared by state-licensed pharmacies for patients with valid prescriptions.

PharmaTher emphasized that these PCAC recommendations mark "an important potential step toward establishing a responsible regulatory framework for the development, compounding and clinical evaluation of personalized peptide medicines in the United States." However, the company clarified that the PCAC recommendation is advisory and non-binding, not constituting FDA approval or authorization for compounding under Section 503A. It highlighted that compounded drugs are not FDA-approved or evaluated for safety, effectiveness, or quality, and all related activities will comply with applicable laws and regulations.

Overcoming Challenges in Current Peptide Care Delivery

The company identified significant limitations in the existing peptide care landscape, including restricted dosage options, inconvenient administration methods, concerns about peptide quality and consistency, and limited personalization capabilities. PharmaTher noted that healthcare providers and pharmacies often lack integrated technology, validated formulations, and scalable systems for producing customized peptide products.

Fabio Chianelli, Chairman and CEO of PharmaTher, stated, "Patients and healthcare providers should not have to rely on a one-size-fits-all approach when individual treatment needs can differ significantly. Personaliz3D Peptides™ is being built to make personalized peptide care more precise, convenient, connected and manufactured under strict quality and GMP-aligned standards." The company suggested that 3D printing could enable qualified providers to produce formulations tailored to specific dosing, combinations, and release profiles while ensuring quality through GMP standards and Certificates of Analysis.

Strategic Three-Pillar Framework: Connect, Personalize, Deliver

PharmaTher outlined a three-part strategy for Personaliz3D Peptides™. The first pillar, "Connect," focuses on developing a personalized peptide telemedicine platform at PersonalizedPeptidesRx.com to link eligible patients with qualified healthcare providers for assessment and ongoing oversight.

The second pillar, "Personalize," involves leveraging 3D printing and AI to create proprietary peptide formulations, protocols, and dosage formats for qualified providers, including 503A compounding pharmacies. Potential personalization features include patient-specific dosing, micro-dosing, combination formulations, varied release profiles, and alternative formats such as tablets, oral films, gels, chews, gummies, suppositories, and patches.

The third pillar, "Deliver," aims to build partnerships with 503A compounding pharmacies, physicians, clinics, hospitals, researchers, technology providers, and pharmaceutical companies to support compliant development, preparation, and delivery of personalized peptide solutions while maintaining professional and regulatory responsibilities.

Proprietary Formulation Development and Technology Integration

Personaliz3D Peptides™ plans to integrate 3D printing and AI technologies to enhance treatment design. AI is expected to assist in developing and optimizing formulations, protocols, and patient-specific treatment pathways. The division intends to create proprietary formulations and protocols for use by qualified providers within its network.

Initial priorities include launching the PersonalizedPeptidesRx.com telemedicine platform, developing proprietary peptide formulations and protocols, creating alternative and non-invasive dosage formats, advancing precise dosing and combination capabilities, establishing collaborations with 503A compounding pharmacies and healthcare providers, developing training and certification programs, integrating pharmacy, physician, and patient data, and pursuing intellectual property related to production methods, formulations, protocols, software, and personalized medicine technologies.

Partnership-Centric Commercialization Approach

PharmaTher revealed a commercialization strategy aimed at generating revenue from multiple streams. These include personalized peptide solutions via the telemedicine platform, 3D printing systems and equipment placements with associated services, telemedicine and pharmacy platform participation, licensing of proprietary formulations, protocols, software, and AI tools, consumables and manufacturing materials, formulation development, small-batch manufacturing services, training and certification programs, as well as sales, royalties, and milestone payments from proprietary or partnered products.

This model is designed to enable independent pharmacies and healthcare providers to engage in a wider personalized peptide platform while retaining responsibility for their professional, regulatory, and patient-care duties. PharmaTher is actively building an integrated network of qualified pharmacy, healthcare, technology, and supply partners to support product development, GMP-compliant manufacturing, data integration, and future delivery of personalized peptide solutions.

Artificial Intelligence and 3D Printing Integration

The company highlighted the critical role of AI and 3D printing in its operations. It proposed that 3D printing could overcome traditional peptide compounding limitations by producing formulations tailored to specific dosing, combinations, and release profiles, ensuring quality through GMP standards and Certificates of Analysis.

AI capabilities are expected to further aid in formulation development and optimization, as well as patient-specific treatment pathways. However, the announcement did not disclose detailed technical information about the AI systems or the current development status of the 3D printing platform.

Development of Alternative Delivery Formats

A core element of the division's strategy is creating alternative pharmaceutical delivery formats beyond traditional injectable or liquid forms. Potential formats include gummies, oral films, tablets, gels, chews, suppositories, and patches. These alternatives, combined with precise dosing, aim to offer patients more convenient and personalized peptide options.

This approach marks a shift from traditional peptide compounding, which is often limited to fixed doses and injectable or liquid forms. PharmaTher suggested that combining personalized dosing with alternative formats could improve patient preferences and treatment adherence, though no clinical or patient satisfaction data were provided.

Building a Network of Healthcare Providers and Pharmacies

PharmaTher plans to establish collaborations with 503A compounding pharmacies and healthcare providers as a foundational aspect of Personaliz3D Peptides™. Initial efforts include forming these partnerships and developing training, certification, and onboarding programs.

The company stressed that partner pharmacies and providers will maintain responsibility for their professional, regulatory, manufacturing, and patient care obligations. While actively constructing an integrated network of qualified partners, PharmaTher did not disclose the number of partnerships or specific timelines.

Regulatory and Compliance Disclosures

PharmaTher reiterated that the PCAC recommendation is advisory and non-binding, not equating to FDA approval or authorization for compounding under Section 503A. It emphasized that compounded drugs are not FDA-approved or evaluated for safety, effectiveness, or quality, and all related activities will adhere to applicable laws and regulations.

The announcement included forward-looking statements subject to risks and uncertainties, such as the FDA potentially not accepting PCAC recommendations, changes in regulatory requirements, restrictions on peptide bulk substances, challenges in developing or launching PersonalizedPeptidesRx.com, and uncertainties regarding 3D printing technology development, validation, GMP compliance, commercialization, and adoption. Additionally, the company may face difficulties establishing commercial partnerships or developing viable products and services.

Immediate Objectives and Market Positioning

PharmaTher intends for Personaliz3D Peptides™ to bridge fragmented aspects of the current peptide care ecosystem by providing tools, formulations, protocols, and partnerships to help qualified healthcare providers offer individualized peptide solutions. The platform aims to simplify the process by enabling patient assessment by physicians, personalized prescriptions, and connection to qualified pharmacies capable of preparing prescribed products.

The goal is to create an integrated ecosystem where patients access convenient, personalized peptide options; physicians prescribe tailored doses, combinations, and delivery formats; pharmacies obtain proprietary formulations, technologies, training, and support; and researchers and pharmaceutical companies develop and evaluate new peptide products and protocols. The immediate focus is on launching the PersonalizedPeptidesRx.com telemedicine platform and developing proprietary formulations and protocols. No immediate impact on share price was indicated in available public information.